PharmiWeb3d
Smart Insulin Pens Market Poised for Significant Growth with Technological Advancements
The global Smart Insulin Pens Market is experiencing substantial growth, driven by the increasing prevalence of diabetes, ...
infectiousdiseaseadvisor.com1d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
PharmiWeb5d
Smart Insulin Pens Market: Comprehensive Analysis and Future Projections (2024-2035)
Market OverviewThe Global Smart Insulin Pens Market was valued USD 102.86 Million in 2022 and is anticipated to reach a value ...
Interesting Engineering on MSN11d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.